Imexpharm FCF Growth
The Year-over-Year Free Cash Flow Growth of Imexpharm (IMP.VN) as of Oct 9, 2026 is -77.16 %. In the previous year, Year-over-Year Free Cash Flow Growth was 215.38 % — a change of -135.82% (lower).
Get this data via API
Financial Data API
FCF Growth
-77.16 %
YoY
-135.82%
Last updated:
The Imexpharm FCF Growth history
3 Years
10 Years
25 Years
Max
| YEAR | FCF Growth | YoY |
|---|---|---|
| -77.16 % | -135.82% | |
| 215.38 % | -257.11% | |
| -137.09 % | -356.65% | |
| 53.41 % | -95.55% | |
| 1,201.09 % | +1,514.72% | |
| 74.38 % | +37.70% | |
| 54.02 % | +159.48% | |
| 20.82 % | -102.54% | |
| -820.58 % | -2,314.22% | |
| 37.06 % | -139.81% | |
| -93.10 % | — |
Imexpharm Stock analysis
Frequently Asked Questions about Imexpharm stock
Year-over-Year Free Cash Flow Growth of Imexpharm is -77.16 % in 2025.
On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Imexpharm since 2006 – with annual values, charts, and detailed analysis.
FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.
To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.
Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Imexpharm historically and in real time.
Growth — Imexpharm
All Key Metrics — Imexpharm
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth